Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
43.07 -3.45 (-7.42%) 04/03/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 43.15 +0.08 (+0.19%) 16:18 ET
News & Headlines for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.5200 (-8.11%)
CSCI : 2.71 (-7.65%)
MLYS : 13.53 (-3.36%)
SWTX : 43.07 (-7.42%)
MGX : 1.2600 (-5.26%)
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

VTI : 263.96 (-5.03%)
XBI : 78.14 (-3.04%)
IWM : 189.65 (-6.42%)
SWTX : 43.07 (-7.42%)
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SWTX : 43.07 (-7.42%)
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

VTI : 263.96 (-5.03%)
XBI : 78.14 (-3.04%)
IWM : 189.65 (-6.42%)
SWTX : 43.07 (-7.42%)
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 43.07 (-7.42%)
SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 43.07 (-7.42%)
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

VTI : 263.96 (-5.03%)
XBI : 78.14 (-3.04%)
IWM : 189.65 (-6.42%)
SWTX : 43.07 (-7.42%)
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

SWTX : 43.07 (-7.42%)
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.5431 (-10.78%)
VYGR : 3.11 (-8.80%)
CSTL : 19.19 (-4.95%)
SWTX : 43.07 (-7.42%)
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

SWTX : 43.07 (-7.42%)

Barchart Exclusives

FedEx Stock Just Hit a New 52-Week Low. Should You Buy the Dip in This Dividend Stock?
Is Fedex a bargain buy or a red flag headed into April 2025? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades